Brenton Saunders - Allergan Plc Chairman
Chairman
Mr. Brenton L. Saunders is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Saunders is Chairman, President and Chief Executive Officer of Allergan and has served in the role of President and Chief Executive Officer since July 2014 and of Chairman since October 2016, having previously served as Chief Executive Officer and President of Forest Laboratories, Inc., and as a director of Forest, prior to its acquisition by Allergan . Prior to that, he served as Chief Executive Officer of Bausch Lomb Incorporated, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Mr. Saunders also held a number of leadership positions at ScheringPlough, including the position of President of Global Consumer Health Care and was named head of integration for the companys merger with Merck Co. and for ScheringPloughs acquisition of Organon BioSciences. Before joining ScheringPlough, Mr. Saunders was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System since 2016.
| Age | 48 |
| Tenure | 8 years |
| Phone | 862 261 7000 |
| Web | http://www.allergan.com |
Allergan Plc Management Efficiency
The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities.The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Allergan Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Allergan Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allergan Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allergan to invest in growth at high rates of return. When we think about Allergan Plc's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| John Craig | Enersys | 63 | |
| Robert Routs | Aegon NV ADR | 70 | |
| Arthur Penn | PennantPark Investment | 61 | |
| Arthur Katsaros | Enersys | 72 | |
| Alexander Wynaendts | Aegon NV ADR | 59 | |
| Irving Bailey | Aegon NV ADR | 74 | |
| Curt Culver | MGIC Investment Corp | 69 | |
| William Connelly | Aegon NV ADR | 63 | |
| Hans Aas | SFL Corporation | 70 | |
| Corien WortmannKool | Aegon NV ADR | 62 | |
Management Performance
| Return On Equity | -0.0913 | |||
| Return On Asset | -0.0564 |
Allergan Plc Leadership Team
Elected by the shareholders, the Allergan Plc's board of directors comprises two types of representatives: Allergan Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allergan. The board's role is to monitor Allergan Plc's management team and ensure that shareholders' interests are well served. Allergan Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allergan Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Walsh, Chief Financial Officer, Executive Vice President | ||
| Robert Bailey, Chief Legal Officer and Corporate Secretary | ||
| Robert Stewart, Executive VP and President of Generic and Global Operations | ||
| Ronald Taylor, Independent Director | ||
| Adriane Brown, Independent Director | ||
| William Meury, Executive Vice President, Chief Commercial Officer | ||
| Brenton Saunders, Chairman of the Board, President, Chief Executive Officer | ||
| Wayne Swanton, Executive Vice President - Global Operations | ||
| Robert Hugin, Independent Director | ||
| Nicholson, Chief R&D Officer | ||
| Christopher Bodine, Independent Director | ||
| Karen Ling, Chief Human Resource Officer, Executive Vice President | ||
| Michael Gallagher, Lead Independent Director | ||
| Paul Bisaro, Executive Chairman | ||
| Thomas Freyman, Independent Director | ||
| Catherine Klema, Lead Independent Director | ||
| James DArecca, Chief Accounting Officer | ||
| Christopher Coughlin, Lead Independent Director | ||
| Nesli Basgoz, Independent Director | ||
| Philippe Schaison, Executive Vice President and President Allergan Medical | ||
| Maria Hilado, CFO and Executive VP | ||
| Joseph Boccuzi, Independent Director | ||
| Patrick OSullivan, Independent Director | ||
| Fred Weiss, Independent Director | ||
| A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary | ||
| Alex Kelly, Chief Communications Officer | ||
| CDavid Nicholson, Executive Vice President, Chief R&D Officer | ||
| Carol Davidson, Independent Director | ||
| Michael Greenberg, Independent Director | ||
| Ron Taylor, Independent Director | ||
| Jonathon Kellerman, Executive Vice President Chief Compliance Officer | ||
| Paul Navarre, Executive Vice President and President International Brands | ||
| James Bloem, Independent Director | ||
| Karina Calzadilla, IR Contact Officer | ||
| Peter McDonnell, Independent Director |
Allergan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allergan Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0913 | |||
| Return On Asset | -0.0564 | |||
| Profit Margin | (0) % | |||
| Operating Margin | 6.84 % | |||
| Current Valuation | 81.41 B | |||
| Shares Outstanding | 328.1 M | |||
| Shares Owned By Insiders | 0.16 % | |||
| Shares Owned By Institutions | 98.25 % | |||
| Number Of Shares Shorted | 15.01 M | |||
| Price To Earning | 24.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allergan Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allergan Plc's short interest history, or implied volatility extrapolated from Allergan Plc options trading.
Pair Trading with Allergan Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allergan Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allergan Plc will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Allergan Plc information on this page should be used as a complementary analysis to other Allergan Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Allergan Stock
If you are still planning to invest in Allergan Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allergan Plc's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |